Results 91 to 100 of about 1,652 (181)

Supplementary Figure S8 from PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer

, 2016
(A) TMA containing 68 patient-derived xenograft (PDX) tumor models stained with PAXIP1 and WEE1 (B-C) Two lung adenocarcinoma PDXs with PAXIP1 and WEE1 staining were used to perform ex vivo 3-D clonogenic assays with various concentrations of AZD1775 and
Eric B. Haura (239755), Nicholas T. Woods (7321022), Uwe Rix (236984), Ankita Jhuraney (15074326), Alvaro N. Monteiro (3825559), Lily Rix (15074329), W. Douglas Cress (10987635), Fumi Kinose (846843), Gabriela Wright (237756), Elizabeth Remily-Wood (1843075), Jhanelle E. Gray (4094155), Stephen G. Brantley (15074335), John M. Koomen (228649), Jodi L. Kroeger (15074332)   +13 more
core   +1 more source

Abstract 4541: Understanding the dose and schedule dependence of efficacy for the Wee1 inhibitor AZD1775 in xenograft and patient derived explant models by mathematical modelling

, 2017
AZD1775 is a highly selective, small-molecule inhibitor of WEE1 being developed to treat patients with advanced solid tumors, as monotherapy and in combination with olaparib.
Susan E. Critchlow, James W. Yates, Jennifer Hare, Urszula M. Polanska, Elaine Cadogan, Adina Hughes, Mark O'Connor   +6 more
core   +1 more source

Figure S4 from A Small-Molecule Inhibitor of WEE1, AZD1775, Synergizes with Olaparib by Impairing Homologous Recombination and Enhancing DNA Damage and Apoptosis in Acute Leukemia

, 2017
FLT3-ITD does not enhance the combinatorial activity of AZD1775 and olaparib. The 32D cell line was transduced with FLT3-ITD or empty vector and treated with olaparib at the indicated doses and/or AZD1775 (100nM) in triplicate for 72 hours. Proliferation
Tamara B. Garcia (8533719), Lori Gardner (14935568), Craig T. Jordan (210141), Chengjing Zhou (3907645), Sujatha Venkataraman (194808), Susan P. Fosmire (14919194), Dmitry Baturin (390190), Rajeev Vibhakar (247074), Christopher C. Porter (8533728), Jonathan C. Snedeker (15074359)   +9 more
core   +1 more source

Supplementary Figure 4 from Inhibition of the ATR–CHK1 Pathway in Ewing Sarcoma Cells Causes DNA Damage and Apoptosis via the CDK2-Mediated Degradation of RRM2

, 2020
Supplementary Figure 4 shows the effect of LY2603618 and AZD1775 on cell cycle and the impact of AZD1775 and AZD6738 on cell growth.
Kelli L. Goss (9711385), William W. Terry (9711391), Stacia L. Koppenhafer (9711388), David J. Gordon (9711394)   +3 more
core   +1 more source

Figure S3 from A Small-Molecule Inhibitor of WEE1, AZD1775, Synergizes with Olaparib by Impairing Homologous Recombination and Enhancing DNA Damage and Apoptosis in Acute Leukemia

, 2017
Inhibition of endogenous P53 in OCI-AML3 cells does not enhance the combinatorial activity of AZD1775 and olaparib. A-C. OCI-AML3 parental (A), MiG (B), and MiG-DDp53 (C) cells were treated with DMSO (vehicle control), olaparib (2 uM), and/or AZD1775 ...
Tamara B. Garcia (8533719), Lori Gardner (14935568), Craig T. Jordan (210141), Chengjing Zhou (3907645), Sujatha Venkataraman (194808), Susan P. Fosmire (14919194), Dmitry Baturin (390190), Rajeev Vibhakar (247074), Christopher C. Porter (8533728), Jonathan C. Snedeker (15074359)   +9 more
core   +1 more source

Genome-scale clustered regularly interspaced short palindromic repeats screen identifies nucleotide metabolism as an actionable therapeutic vulnerability in diffuse large B-cell lymphoma

Haematologica
Diffuse large B-cell lymphoma (DLBCL) is the most common malignancy that develops in patients with ataxia-telangiectasia, a cancer-predisposing inherited syndrome characterized by inactivating germline ATM mutations.
Nicholas Davies, Tegan Francis, Ceri Oldreive, Maria Azam, Jordan Wilson, Philip J. Byrd, Megan Burley, Archana Sharma-Oates, Peter Keane, Sael Alatawi, Martin R. Higgs, Zbigniew Rudzki, Maha Ibrahim, Tracey Perry, Angelo Agathaggelou, Anne-Marie Hewitt, Edward Smith, Constanze Bonifer, Mark O’Connor, Josep V. Forment, Paul G. Murray, Eanna Fennell, Gemma Kelly, Catherine Chang, Grant S. Stewart, Tatjana Stankovic, Marwan Kwok, Alexander Malcolm Taylor   +27 more
doaj   +1 more source

MDB-22. CDK7 inhibition mitigates AZD1775 resistance via chromatin reprogramming in MYC-MB

Neuro-Oncology Pediatrics
Abstract Medulloblastoma (MB) is the most common malignant brain tumor in children, comprising ∼20% of pediatric brain tumors. MB is a heterogeneous disease, with clinical outcomes heavily influenced by molecular subgroups. Among these, Group 3 MB, characterized by MYC amplification, exhibits the poorest prognosis, with a high ...
Kiara Smart, Dong Wang, Ammu Suresh, Rajeev Vibhakar, Bethany Veo   +4 more
openaire   +1 more source

Figure S8 from A Small-Molecule Inhibitor of WEE1, AZD1775, Synergizes with Olaparib by Impairing Homologous Recombination and Enhancing DNA Damage and Apoptosis in Acute Leukemia

, 2017
AZD1775 enhances the anti-proliferative effect of olaparib in AML patient samples with high baseline apoptosis or limited colony-forming ability. A and B.
Tamara B. Garcia (8533719), Lori Gardner (14935568), Craig T. Jordan (210141), Chengjing Zhou (3907645), Sujatha Venkataraman (194808), Susan P. Fosmire (14919194), Dmitry Baturin (390190), Rajeev Vibhakar (247074), Christopher C. Porter (8533728), Jonathan C. Snedeker (15074359)   +9 more
core   +1 more source

Harnessing machine learning to find synergistic combinations for FDA-approved cancer drugs

Scientific Reports
Combination therapy is a fundamental strategy in cancer chemotherapy. It involves administering two or more anti-cancer agents to increase efficacy and overcome multidrug resistance compared to monotherapy. However, drug combinations can exhibit synergy,
Tarek Abd El-Hafeez, Mahmoud Y. Shams, Yaseen A. M. M. Elshaier, Heba Mamdouh Farghaly, Aboul Ella Hassanien   +4 more
doaj   +1 more source

Replication Stress Leading to Apoptosis within the S-phase Contributes to Synergism between Vorinostat and AZD1775 in HNSCC Harboring High-Risk TP53 Mutation

, 2017
Purpose: The cure rate for patients with advanced head and neck squamous cell carcinoma (HNSCC) remains poor due to resistance to standard therapy primarily consisting of chemoradiation.
Natalie L. Silver, Curtis R. Pickering, Marek Kimmel, Jing Wang, Abdullah A. Osman, Noriaki Tanaka, Antje Lindemann, Jiping Wang, Lin Tang, Ameeta A. Patel, Xiayu Rao, Tseng-Cheng Chen, Hideaki Takahashi, Faye Johnson, Frederico O. Gleber-Netto, Nene N. Kalu, Roman Jaksik, Mitchell J. Frederick, Jeffrey N. Myers, Siqing Fu, Walter N. Hittelman   +20 more
core   +1 more source